

Deals and M&A

Biotech and Medtech



889 deals worldwide

Total worth \$ 79 Bn
Average deal value \$ 410 M



36% of deals in oncology



10% in neurology

42% of deals are licensing agreements



36% antibodies



15% protein / peptide



8% cell therapy



8% biomarker



38% of deals for biologics



21% for small molecules

American companies are present in 9 out of 10 top deals

Top 3 deals worldwide

Top 3 deals with French biotech



Sources: BioCentury (January 2018); France Biotech



112 M&A operations worldwide

Total worth > \$ 83 Bn
Average deal value \$ 1.4 Bn

90 acquisitions
22 mergers

Stage of target company at signing

Main therapeutic areas of companies




25% in oncology



11% infectious diseases



7% in neurology



6% metabolism



32% for biologics



26% for small molecules



22% antibodies



17% protein / peptide



17% vaccine

Top 3 M&A operations
Full acquisitions



Sources: BioCentury (January 2018); France Biotech